Categorynews

4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

November 18, 2020 Off By BusinessWire

EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. Nancy Miller-Rich brings 35 years of experience in the healthcare industry, with significant expertise in business development and commercial strategy. Shawn Tomasello brings over 30 years of experience in the life sciences industry, with significant expertise building and leading commercial organizations.

“We are thrilled to welcome both Nancy and Shawn to our Board of Directors as we embark on the next phase of our evolution,” said David Kirn, MD, co-founder and chief executive officer of 4DMT. “Both appointments reflect our commitment to build a fully-integrated biopharmaceutical company. We look forward to benefiting from Nancy and Shawn’s extensive commercialization experience as we advance 4DMT’s next-generation gene therapy programs.”

Ms. Miller-Rich has served in several leadership roles at Merck and, prior to the merger of the two companies, at Schering-Plough. She was most recently Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support and before that Group Vice President, Consumer Care, Global New Ventures and Strategic Commercial Development. Ms. Miller-Rich currently serves on the Board of Directors of Aldeyra Therapeutics as well as a number of private and not-for-profit entities. She received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.

Ms. Tomasello most recently served as Chief Commercial Officer of Kite Pharma (subsequently Kite, a Gilead Company), where she led the commercialization of Yescarta, the first approved CAR-T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin lymphoma. (Read more…) Prior to joining Kite, she served as Chief Commercial Officer at Pharmacyclics, Inc. (subsequently Pharmacyclics, an Abbvie Company), during which time the brand Imbruvica was awarded the prestigious 2015 Prix Galien Award for Best Pharmaceutical Agent. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. Prior to this, she was National Director of Hematology for Rituxan at Genentech, representing the most significant portion of the company’s product revenue during her tenure. Ms. Tomasello currently serves on the Board of Directors of the following publicly-held companies: Urogen Pharma, Gamida Cell, and Mesoblast. Ms. Tomasello holds a B.S. degree in marketing from the University of Cincinnati and an M.B.A. from Murray State University, KY.

About 4DMT

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.